Optimer Pharmaceuticals to Present at November 2009 Investor Conferences

SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

• Oppenheimer's 20th Annual Healthcare Conference on Wednesday, November 4, 2009 at 1:00 p.m. Eastern Time at the Waldorf-Astoria in New York City.
• Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 10:25 a.m. Eastern Time at the St. Regis in New York City.
  

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Live audio webcasts of these presentations will be accessible on the Investors page of the Company's website at www.optimerpharma.com, under the investors section. Replays of these presentations will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of infectious diarrhea in travelers. Additional information can be found at http://www.optimerpharma.com.

    Contacts

    Optimer Pharmaceuticals, Inc.
    Christina Donaghy, Corporate Communications Manager
    John D. Prunty, Chief Financial Officer & VP Finance
    858-909-0736

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President
    619-849-6005

SOURCE Optimer Pharmaceuticals, Inc.